Headlines this Week
Contributed by Max Berkovich
- International stocks outperformed U.S. peers while U.S. small-capitalization stocks continued their strong march higher and outperformed mid and large capitalization stocks for the week.
- The U.S. Federal Reserve indicated that they are poised to halt their balance sheet reductions and possibly hold interest rates steady.
- U.S and China trade negotiations are going well, reportedly. They have agreed upon 6 memorandums of understanding. The memorandums deal with six structural issues; forced technology transfer and cyber theft, intellectual property rights, currency, agriculture, non-tariff barriers to trade and services.
- The European Union (EU) threatened to retaliate by imposing targeted tariffs on Caterpillar (CAT) and Xerox (XRX) if the U.S. follows through with its threat to impose duties against the European automotive industry.
- In the latest Brexit twist, the European Union (EU) expects the United Kingdom to ask for a 3-month delay. However, EU Parliamentary election loom in May, there may be less willingness to let the process drag on any later.
The Week Ahead
- Strategic holdings Booking Holding Inc. (BKNG) & retailer TJX Companies Inc. (TJX) are due to release earnings.
- Tuesday & Wednesday sees Federal Reserve Chairman Powell testifying in Congress.
- British Prime Minister May is scheduled to hold a Brexit speech as the clock ticks down to the March 29th deadline.
- 4th Quarter 2018 preliminary Gross Domestic Product (GDP) index will be released on Thursday.
Stock Highlights from Max
Academy Awards: Best Sector award goes to materials thanks to a moving performance from best actor winner. The worst sector was a unanimous pick, health care thanks to a forgettable adaptation of an old script by…
- CVS Health Corp. (CVS) stuck to a familiar script with a beat on earnings but a miss on revenue and a big cut to guidance. The Academy took note that many are dismissing this report as transitory as the company just completed a transformative acquisition of a health insurer. Hopefully, the bad reviews are in the past and the company is positioned well to capitalize on a 5.5% annual increase in spending on health care that the Center for Medicare & Medicaid is predicting for the next decade.
- Best supporting actor despite being in the worst sector was Merck & Co. (MRK). The pharmaceutical giant announced it was acquiring Immune Design (IMDZ) for $300 Million. IMDZ’s anti-tumor response seems to be the prize, as it showed good results in conjunction with Merck’s Keytruda cancer antibody.
- Best actor this week goes to Albemarle Corp. (ALB) which delivered a moving quarter as it beat consensus expectations. The mining and specialty chemicals company reported that lithium pricing was up 9% in 2018 and volume had increased as well. The company also guided for double-digit earnings per share growth in 2019.
Founded in 1979, Strategic is a leading investment and wealth management firm managing and advising on client assets over $1 billion.Overview
Strategic Financial Services, Inc. is a SEC-registered investment advisor. The term “registered” does not imply a certain level of skill or training. “Registered” means the company has filed the necessary documentation to maintain registration as an investment advisor with the Securities and Exchange Commission.
The information contained on this site is for informational purposes and should not be considered investment advice or a recommendation of any particular security, strategy or investment product. Every client situation is different. Strategic manages customized portfolios that seek to properly reflect the particular risk and return objectives of each individual client. The discussion of any investments is for illustrative purposes only and there is no assurance that the adviser will make any investments with the same or similar characteristics as any investments presented. The investments identified and described do not represent all of the investments purchased or sold for client accounts. Any representative investments discussed were selected based on a number of factors including recent company news or earnings release. The reader should not assume that an investment identified was or will be profitable. All investments contain risk and may lose value. There is no assurance that any investments identified will remain in client accounts at the time you receive this document.
Some of the material presented is based upon forward-looking statements, information and opinions, including descriptions of anticipated market changes and expectations of future activity. Strategic Financial Services believes that such statements, information, and opinions are based upon reasonable estimates and assumptions. However, forward-looking statements, information and opinions are inherently uncertain and actual events or results may differ materially from those reflected in the forward-looking statements. Therefore, undue reliance should not be placed on such forward-looking statements, information and opinions.
No content on this website is intended to provide tax or legal advice. You are advised to seek advice on these matters from separately retained professionals.
All index returns, unless otherwise noted, are presented as price returns and have been obtained from Bloomberg. Indices are unmanaged and cannot be purchased directly by investors.
Advisory Services offered through Strategic Financial Services, Inc. Strategic Financial Services, Inc. and Cadaret, Grant & Co., Inc. are not affiliated.